I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to ...

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel ...

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Arcellx Inc (ACLX – Research Report). The ...

UBS analyst Ashwani Verma raised the firm’s price target on Arcellx (ACLX) to $114 from $106 and keeps a Buy rating on the shares. UBS believes ...

With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off ...

NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports. They presently ...

Analysts have recently evaluated Arcellx and provided 12-month price targets. The average target is $107.71, accompanied by a ...

--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable ...